[Calmette-Guerin bacillus in the prophylaxis of superficial bladder tumors. Our experience and our doubts].
OBJECTIVE
This study was conducted to determine the efficacy of our BCG dose and schedule for prophylactic therapy in superficial bladder tumors.


METHODS
Following complete TUR, 81 mg intravesical BCG were administered weekly for six weeks and for nightly another six times. The patients were evaluated every three months by cytology, cystoscopy and routine analysis.


RESULTS
21/25 patients completed the treatment. At 15.5 months median follow-up, 18/21 (85.7%) were disease-free, 2/21 (9.5%) had recurrence and 1/21 (4.7%) showed disease progression.


CONCLUSIONS
BCG is the most effective prophylactic therapy for superficial bladder tumors currently available. The ideal dose, treatment schedule and its mechanism of action are as yet unknown.
Moyano Calvo
J L
JL
Hospital La Princesa, Universidad Autónoma de Madrid, España.
Sanz Sacristán
J
J
Teba del Pino
F
F
Fernández Arjona
M
M
Peinado Ibarra
F
F
Mélon Rey
F
F
Herrero Torres
L
L
Rabadán Ruiz
M
M
Arellano Gañán
R
R
Albacete Almodóvar
P
P
D001500:BCG Vaccine / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D001749:Urinary Bladder Neoplasms / Q000517:prevention & control*
D001500:BCG Vaccine
Bacilo de Calmette-Guerin en la profilaxis de los tumores superficiales de vejiga. Nuestra experiencia y nuestras dudas.